同和药业(300636) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥137,346,511.89, representing a 42.06% increase compared to ¥96,684,382.42 in the same period last year[7] - Net profit attributable to shareholders was ¥20,137,702.87, up 27.53% from ¥15,790,754.32 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥19,455,186.62, reflecting a 27.87% increase from ¥15,214,417.49 in the previous year[7] - The net cash flow from operating activities reached ¥21,624,541.20, a significant increase of 72.75% compared to ¥12,518,035.44 in the same quarter last year[7] - Basic earnings per share decreased by 20.26% to ¥0.1566 from ¥0.1964 in the previous year[7] - Operating costs for the same period were ¥113,942,411.54, up from ¥78,980,447.86 year-on-year[58] - The net profit for the first quarter of 2021 was CNY 19,307,114.92, an increase of 20.5% compared to CNY 16,074,298.84 in the same period last year[62] - Operating profit reached CNY 21,180,977.78, up from CNY 18,162,522.80, reflecting a growth of 11.1% year-over-year[62] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,466,755,142.96, a slight decrease of 0.06% from ¥1,467,668,918.00 at the end of the previous year[7] - The company's total assets amounted to CNY 1,466,755,142.96, a slight decrease from CNY 1,467,668,918.00 at the end of 2020[52] - The company's total liabilities decreased to CNY 630,116,720.54 from CNY 651,168,198.45, reflecting a reduction of approximately 3.2%[51] - Total liabilities decreased to ¥629,495,396.81 from ¥649,834,252.38, indicating a reduction in financial obligations[55] - Short-term borrowings decreased to CNY 135,542,390.00 from CNY 209,370,860.00, a reduction of approximately 35.3%[51] - Long-term borrowings increased to CNY 89,000,000.00 from CNY 69,000,000.00, representing a rise of about 29.0%[51] Shareholder Information - The company reported a total of 7,325 common shareholders at the end of the reporting period[11] - The top shareholder, Pang Zhengwei, holds 18.19% of the shares, with 23,396,874 shares, of which 17,547,655 are pledged[11] Cash Flow - Cash flow from operating activities rose by 72.75%, totaling CNY 21.62 million, compared to CNY 12.52 million in the prior year[21] - The company's cash and cash equivalents decreased to CNY 138,985,046.11 from CNY 280,403,523.68, representing a decline of approximately 50.5%[49] - The ending balance of cash and cash equivalents was CNY 136,464,246.11, down from CNY 236,029,503.22 at the end of the previous year[67] - The company reported cash outflow from investing activities of CNY 119,618,570.55, which is a substantial increase from CNY 23,165,957.10 in the same period last year[66] - The net cash flow from financing activities was negative CNY 57,109,620.00, a significant decrease from a positive CNY 210,858,130.18 in the previous year[67] Investment and Projects - The company plans to submit 2-4 product registrations in Europe, South Korea, the United States, and Japan in 2021 to enhance its export market[24] - The company is expanding its second plant project, which includes the production of 100 tons of 7-methoxy naphthalene ketone and 30 tons of rivaroxaban, with construction nearing completion[34] - The company approved an investment of up to 95 million RMB for technical renovation projects in the first plant area, including the construction of new public engineering buildings and solvent tank areas[35] - The total amount of raised funds is 360 million RMB, with 84.93 million RMB invested in the current quarter and a cumulative investment of 220.68 million RMB[37] - The cumulative investment amount represents 62.31% of the total planned investment[39] Risk Management and Compliance - The company is actively monitoring policy changes in the pharmaceutical industry to mitigate risks associated with regulatory compliance and market competition[27] - The company has established a dedicated team for registration and certification to ensure the renewal of essential operating qualifications, minimizing the risk of operational disruptions[28] - The company has implemented a comprehensive safety management system to prevent production accidents and ensure compliance with environmental standards[30] - The company maintains a strict quality management system in accordance with GMP standards to control product quality throughout the production process[31] Employee and Operational Information - Employee compensation payments increased to CNY 25,817,601.35 from CNY 21,239,535.26, reflecting a rise of 21.5% year-over-year[66] - The company aims to enhance product competitiveness and core competencies to achieve its vision of becoming a leading pharmaceutical enterprise in Jiangxi, with no significant changes in the execution of the annual business plan during the reporting period[25] Miscellaneous - The first quarter report was not audited, indicating that the figures may be subject to change upon final review[73] - The company did not apply the new leasing standards for the current year, as it was not applicable[71]